<?xml version="1.0" encoding="UTF-8"?>
<p>This study was designed as a phase I, open‐label, single‐arm, single‐center trial to evaluate the safety and feasibility of intraventricular allograft transplantation of UCB‐derived MSCs into premature infants with severe IVH. The protocol was reviewed and approved by the Korean Food and Drug Administration (30261) and by the Institutional Review Board of the Samsung Medical Center in Seoul, Korea (IRB No. 2014–06‐103). The study was registered on 
 <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">http://clinicaltrials.gov</ext-link> (NCT02274428). The Clinical Trial Center of Samsung Medical Center (Seoul, South Korea) acted as the external monitor of the present study and performed intensive and cautious external monitoring. The informed consent document was reviewed at least 3 times by all parents, and the principle investigator or coinvestigator. Full written informed consent was obtained with particular attention to the understanding of potential safety issues, and the fact that therapeutic benefit was neither expected nor promised.
</p>
